BMAL1 and Parkinsonism: 1-methyl-4-phenyl-1,2,4,5-tetrahydropyridine (MPTP)-treated Parkinson’s mouse model showed inactivation of the main circadian transcriptional factor, BMAL1/ARNTL, resulting in motor dysfunction, dopaminergic neuron loss, and aggravated activated microglia-mediated neuroinflammation, displaying the role of BMAL1/ARNTL in microglial pro-inflammatory responses [383].